Legal Onslaught: Musk’s Authority, USAID, and Deportation Cases Dominate US Courts
The United States is witnessing a wave of high-stakes lawsuits that challenge the boundaries of executive power and individual rights. At the forefront is a lawsuit led by New Mexico, arguing that Elon Musk’s role as head of the Department of Government Efficiency (DOGE) violates the Appointments Clause of the Constitution. The states contend that Musk, who reports solely to President Trump, holds “unprecedented and seemingly limitless access across the federal government,” making him a “principal officer” who must be formally nominated by the president and confirmed by the Senate. The lawsuit emphasizes that Musk’s power remains unchecked, raising concerns about accountability and the separation of powers.
Similar constitutional arguments were raised in a separate suit filed by current and former employees of the United States Agency for International Development (USAID). After Musk and his DOGE team effectively shuttered the agency, the employees challenged the legality of his actions. In another development, a federal judge granted a request by 22 state attorneys general to halt the Trump administration’s massive cuts to federal research agencies, which would have affected equipment, maintenance, utilities, and support staff. These cases collectively underscore a growing judicial scrutiny of the administration’s aggressive use of executive authority.
Beyond the executive branch, the courts are also addressing issues of free speech and immigration. Pro-Palestine advocate Mahmoud Khalil has filed a lawsuit against Trump administration officials and three private groups—the Heritage Foundation, Betar, and Canary Mission—alleging a coordinated conspiracy to target and deport him. The lawsuit, filed in Manhattan federal court, claims that the Heritage Foundation’s “Project Esther” blueprint aims to dismantle the pro-Palestine movement by targeting prominent non-citizens and conflating advocacy with anti-Jewish sentiment. This case highlights the tension between national security concerns and civil liberties.
In the corporate sphere, Danish drugmaker Novo Nordisk has filed 14 new lawsuits against the sale of unapproved versions of semaglutide, the active ingredient in its popular drugs Wegovy and Ozempic. These legal actions reflect the company’s efforts to protect its intellectual property and ensure patient safety. As these diverse cases unfold, they collectively illustrate a nation grappling with fundamental questions about power, accountability, and the rule of law.
Shimanta Das 
